Compared to monoclonal anti-PD-1 and anti-PD-L1 antibodies, Hanmi bsAb promoted the secretion of cytokines such as IL-2 and IFN-γ more significantly and showed stronger anti-cancer efficacy in vitro and in vivo [76]. This evidence concerns the gene PDCD1 and cancer.